- Home
- ESEA vs PRME Comparison
ESEA vs PRME Comparison
Compare ESEA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | PRME |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.0M | 553.2M |
| IPO Year | 2005 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ESEA | PRME |
|---|---|---|
| Price | $76.49 | $3.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $62.00 | $7.56 |
| AVG Volume (30 Days) | 33.3K | ★ 2.7M |
| Earning Date | 06-17-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | $1.74 | $7.06 |
| Revenue Next Year | $1.07 | $47.01 |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $51.00 | $2.67 |
| 52 Week High | $79.67 | $6.94 |
Technical Indicators
Market Signals| Indicator | ESEA | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 52.18 |
| Support Level | $62.62 | $3.16 |
| Resistance Level | $79.23 | $3.32 |
| Average True Range (ATR) | 3.01 | 0.21 |
| MACD | -0.17 | 0.04 |
| Stochastic Oscillator | 69.07 | 57.86 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.